CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Panobinostatdrug
Likely dose
Panobinostat 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00777049
NCT00777049Phase 2Completed
CompareCT.gov

A Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

Translational Research in Oncology·interventional·Posted Oct 22, 2008·Updated Jul 15, 2016

In Brief

A Phase 2 clinical trial evaluating Panobinostat for Breast Cancer. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the benefit of oral panobinostat monotherapy given to women with HER2-negative locally recurrent or metastatic breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 22, 2008
Enrollment StartFeb 1, 2009
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 17.7 years ago

Interventions

Panobinostatdrug

Hard gelatine capsule - 5mg and 20mg